Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina

Coronary artery disease is a leading cause of death in the United States. Angina is encountered frequently in clinical practice. Effective management of patients with coronary artery disease and stable angina should consist of therapy aimed at symptom control and reduction of adverse clinical outcom...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The American journal of medicine Ročník 124; číslo 8; s. 681
Hlavní autoři: Deedwania, Prakash C, Carbajal, Enrique V
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.08.2011
Témata:
Acetanilides - therapeutic use
Adrenergic beta-Antagonists - therapeutic use
Angina Pectoris - drug therapy
Angina Pectoris - surgery
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Benzazepines - therapeutic use
Calcium Channel Blockers - therapeutic use
Cardiovascular Agents - adverse effects
Cardiovascular Agents - pharmacology
Cardiovascular Agents - therapeutic use
Coronary Disease - drug therapy
Coronary Disease - surgery
Drug Therapy, Combination
Humans
Hypolipidemic Agents - therapeutic use
Myocardial Revascularization - statistics & numerical data
Myocardial Revascularization - trends
Nitrates - therapeutic use
Piperazines - therapeutic use
Ranolazine
Treatment Outcome
ISSN:1555-7162, 1555-7162
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Coronary artery disease is a leading cause of death in the United States. Angina is encountered frequently in clinical practice. Effective management of patients with coronary artery disease and stable angina should consist of therapy aimed at symptom control and reduction of adverse clinical outcomes. Therapeutic options for angina include antianginal drugs: nitrates, beta-blockers, calcium channel blockers, ranolazine, and myocardial revascularization. Recent trials have shown that although revascularization is slightly better in controlling symptoms, optimal medical therapy that includes aggressive risk factor modification is equally effective in reducing the risk of future coronary events and death. On the basis of the available data, it seems appropriate to prescribe optimal medical therapy in most patients with coronary artery disease and stable angina, and reserve myocardial revascularization for selected patients with disabling symptoms despite optimal medical therapy.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1555-7162
1555-7162
DOI:10.1016/j.amjmed.2011.02.036